Turnstone Biologics Corp

Turnstone Biologics Corp(TSBX)の株式分析

$0.355

+0.005 (+1.43%)終値時点

Loading chart…
High
0.365
Open
0.350
VWAP
0.36
Vol
283.77K
Mkt Cap
69.15M
Low
0.350
Amount
101.21K
EV/EBITDA, TTM
0.57

Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions.

バリュエーション指標

The current forward P/E ratio for Turnstone Biologics Corp (TSBX) is -1.58, compared to its 5-year average forward P/E of -0.83.

Forward P/E

Fair
5Y Average P/E
-0.83
Current P/E
-1.58
割高
0.05
割安
-1.71

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.16
Current EV/EBITDA
0.57
割高
0.88
割安
-0.57

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
割高
0.00
割安
0.00

Alphio AI Price Scenarios for TSBX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TSBX

$0.39

シナリオ価格

B

Base

Base · 50%TSBX

$0.33

シナリオ価格

B

Bear

Bear · 25%TSBX

$0.26

シナリオ価格

イベントタイムライン

2025-08-11 (ET)

09:09:02

Xoma closes tender offer for Turnstone Biologics

2025-06-27 (ET)

07:36:08

Xoma to acquire Turnstone Biologics for $0.34 in cash per share

2025-03-30 (ET)

17:40:46

Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year

2025-02-04 (ET)

08:02:22

Turnstone to discontinue all clinical studies, explore strategic alternatives

2024-11-12 (ET)

15:44:54

Turnstone Biologics reports Q3 EPS (74c), consensus (86c)

ニュース

TSBX FAQ — answered by Alphio AI

Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める